|
A presentation by investigators participating in the Breast and
Prostate Cancer Cohort Consortium (BPC3) to the National Cancer Advisory
Board (NCAB) is being videocast live from 2:15 p.m. to 3:15 p.m.
Tuesday, June 7, 2005, via the National
Institutes of Health's (NIH) Web site. The speakers' PowerPoint
presentations are provided below. A briefing
paper (PDF) also is available. The NCAB meeting is taped and will be
archived for later viewing via the NIH videocast system.
In 2003 through the Epidemiology and Genetics Research Program (EGRP),
the BPC3 received a 4-year grant to study the role of genetic variations
in steroid receptor hormone pathways, the insulin-like growth factor (IGF)
pathway, and associated receptor proteins in the etiology of breast and
prostate cancer. Data and biospecimens are being pooled from 6 large cohorts
to conduct research on gene-environment interactions in cancer etiology.
The BPC3 combines the resources of these large prospective cohorts, three
genomic facilities, and epidemiologists, population geneticists, and biostatisticians
from multiple institutions. Data are drawn from 8,850 patients with prostate
cancer and 6,160 patients with breast cancer.
The BPC3 is the first project to be conducted through the Consortium
of Cohorts, a joint initiative of NCI's Division
of Cancer Epidemiology and Genetics (DCEG) and the Division
of Cancer Control and Population Sciences (DCCPS), of which EGRP is
a part.
 |
Robert T. Croyle, Ph.D.
Director
Division of Cancer Control and Population Sciences
National Cancer Institute |
 |
Edward J. Trapido, Sc.D.
Associate Director
Epidemiology and Genetics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute, NIH
Progress Update: Breast
and Prostate Cancer Cohort Consortium (BPC3)
|
 |
Michael J. Thun, M.D., M.S.
Vice President
Epidemiology and Surveillance Research
American Cancer Society
Overview Study Design,
Goals, and Achievements
|
 |
David M. Altshuler, M.D., Ph.D.
Assistant Professor of Genetics and Medicine
Department of Molecular Biology
Harvard Medical School and
Massachusetts General Hospital
Population Genetics/Genomics
Subgroup: SNP Discovery and Haplotype Analysis
|
 |
David J. Hunter, Sc.D.
Professor of Epidemiology and Nutrition
Harvard School of Public Health
Channing Laboratory
Management and Integration Across
Sites, Initial Results, and Plans for the Future
|
The Principal Investigators of the BPC3 are: Dr. Hunter, Harvard
Cohorts (Physicians' Health Study I and II, Nurses' Health Study,
Health Professionals Follow-up Study, and Women's Health Study);
Dr. Thun, American Cancer Society's Cancer Prevention Study-II
(ACS CPS-II); Elio Riboli, M.D., Sc.M., M.P.H., International Agency
for Research on Cancer (IARC) (relocated to Imperial College, London,
in late 2005), European Prospective Investigation into Cancer and
Nutrition (EPIC) Study; and Brian Henderson, M.D., University of
Southern California/Norris Comprehensive Cancer Center, Multiethnic
Cohort Study.
In addition, two cohorts participating in BPC3 are part of DCEG, an intramural
research arm of NCI. The Principal Investigators are Richard Hayes, D.D.S.,
Ph.D., Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening
Trial; and Demetrius Albanes, M.D., Alpha-Tocopherol, Beta-Carotene Cancer
Prevention (ATBC) Study.
More information about the Cohort Consortium
and BPC3
|
